Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;13(10):617-619.

The Use of Nonselective Beta Blockers for Treatment of Portal Hypertension

Affiliations

The Use of Nonselective Beta Blockers for Treatment of Portal Hypertension

Guadalupe Garcia-Tsao. Gastroenterol Hepatol (N Y). 2017 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr Garcia-Tsao has no relevant conflicts of interest to disclose.

References

    1. Albillos A, Zamora J, Martinez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis. Hepatology. published online May 25, 2017. doi:10.1002/hep.29267. - PMC - PubMed
    1. Bang UC, Benfield T, Hyldstrup L, Jensen JE, Bendtsen F. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Liver Int. 2016;36(9):1304–1312. - PubMed
    1. Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(8):1096–1104.e9. - PubMed
    1. Garcia-Tsao G. Beta blockers in cirrhosis: the window re-opens. J Hepatol. 2016;64(3):532–534. - PubMed
    1. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310–335. - PubMed

LinkOut - more resources